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At a Glance Commentary 
Scientific Knowledge on the Subject: Bronchiolitis disease severity varies significantly among 
infants, which cannot be explained by currently known risk factors. Emerging evidence 
indicates that bronchiolitis pathobiology involves a complex interplay among viruses, airway 
microbiome, and host immunity. However, a detailed assessment of the airway metabolome 
and bacterial metagenome (microbiome) has not been performed. 
What This Study Adds to the Field: In this multicenter cohort study, infants with more-severe 
bronchiolitis – defined by the use of positive pressure ventilation – had significantly altered 
nasopharyngeal airway metabolome profiles compared to those with less-severe bronchiolitis. 
Increased sphingolipid metabolism was correlated with higher relative abundance of 
Streptococcus pneumonia and was associated with higher bronchiolitis severity. Our data 
highlight microbe-host interactions in the airway of infants, which may provide a novel 
therapeutic strategy to treat infants with bronchiolitis. 
 
 
This article has an online data supplement, which is accessible from this issue's table of 
content online at www.atsjournals.org 
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ABSTRACT 
Rationale: Bronchiolitis is the most common lower respiratory infection in infants; however, 
it remains unclear which infants with bronchiolitis will develop severe illness. In addition, 
while emerging evidence indicates associations of the upper-airway microbiome with 
bronchiolitis severity, little is known about the mechanisms linking airway microbes and host 
response to disease severity.  
Objectives: To determine the relations among the nasopharyngeal airway metabolome 
profiles, microbiome profiles, and severity in infants with bronchiolitis.  
Methods: We conducted a multicenter prospective cohort study of infants (age <1 year) 
hospitalized with bronchiolitis. By applying metabolomic and metagenomic (16S rRNA gene 
and whole genome shotgun sequencing) approaches to 144 nasopharyngeal airway samples 
collected within 24 hours of hospitalization, we determined metabolome and microbiome 
profiles and their association with higher severity, defined by the use of positive pressure 
ventilation (PPV) – i.e., continuous positive airway pressure and/or intubation. 
Measurements and Main Results: Nasopharyngeal airway metabolome profiles 
significantly differed by bronchiolitis severity (P<0.001). Among 254 metabolites identified, 
a panel of 25 metabolites showed high sensitivity (84%) and specificity (86%) in predicting 
the use of PPV. The intensity of these metabolites was correlated with relative abundance of 
Streptococcus pneumoniae. In the pathway analysis, sphingolipid metabolism was the most 
significantly enriched sub-pathway in infants with PPV use compared to those without 
(P<0.001). Enrichment of sphingolipid metabolites was positively correlated with the relative 
abundance of S. pneumoniae. 
Conclusions: While further validation is needed, our multi-omic analyses demonstrate the 
potential of metabolomics to predict bronchiolitis severity and better understand microbial-
host interaction.  
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INTRODUCTION 
 Bronchiolitis, an acute lower respiratory viral infection, is an important public health 
problem in the U.S and worldwide. Indeed, bronchiolitis is the leading cause of infant 
hospitalizations in the US, accounting for 18% of infant hospitalizations (approximately 
130,000 hospitalizations annually) (1, 2). While approximately 40% of children develop 
clinical bronchiolitis in the first two years of life (3), its severity ranges from a minor 
nuisance to fatal (4). Studies have reported several clinical risk factors for higher severity 
(e.g., prematurity, comorbidity); however, it remains unclear which children with 
bronchiolitis will develop severe illness (5), such as bronchiolitis requiring positive pressure 
ventilation (PPV) support. 
 Emerging evidence indicates that bronchiolitis pathobiology involves a complex 
interplay among viruses, airway microbiome, and host immunity (6, 7). For instance, 
dominance of Streptococcus or Haemophilus in the upper airway has been associated with 
higher disease severity (7–9). Yet, little is known about molecular mediators of this interplay. 
Metabolomics, the systematic analysis of functional small-molecules, present pathobiological 
profiles that encompass microbial and host interactions (10–12). For a number of complex 
infectious and inflammatory diseases such as sepsis (13), asthma (14, 15), and cystic fibrosis 
(CF) (16, 17), metabolomic approaches have identified new biomarkers and novel 
pathobiological pathways. However, to date, no study has applied a metabolomics approach 
to infants with bronchiolitis. 
 To address these knowledge gaps, we used nasopharyngeal airway samples from a 
multicenter prospective study of infants hospitalized for bronchiolitis to profile the airway 
metabolome and microbiome, and to determine their relation to disease severity with focusing 
on the use of PPV. The current study also utilized 16S rRNA gene sequence data published 
previously (6, 8, 18). 
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MATERIALS AND METHODS  
Study design, setting, and participants 
 As part of a 17-center, prospective cohort study of 1,016 infants (age <1 year) 
hospitalized for bronchiolitis, based on a priori defined study aim, the current investigation 
analyzed the data of 144 infants with nasopharyngeal metabolomic and microbiome testing 
and determined their relation to disease severity. This cohort, called the 35th Multicenter 
Airway Research Collaboration (MARC-35) (6), was coordinated by the Emergency 
Medicine Network (EMNet) –  a research collaboration comprised of 245 hospitals. The study 
design, setting, participants, and methods of data collection have been reported previously (6, 
8). In brief, MARC-35 site investigators at 17 sites across 14 U.S. states enrolled infants 
hospitalized with an attending physician diagnosis of bronchiolitis during three consecutive 
bronchiolitis seasons from November 1 to April 30 (2011-2014). Bronchiolitis was defined by 
the American Academy of Pediatrics guidelines – acute respiratory illness with some 
combination of rhinitis, cough, tachypnea, wheezing, crackles, and retractions (19). We 
excluded infants who were transferred to a participating hospital >24 hours after the original 
hospitalization, those who were consented >24 hours after hospitalization, or those with 
known heart-lung disease, immunodeficiency, or gestational age <32 weeks. The institutional 
review board at each of the participating hospitals approved the study. Written informed 
consent was obtained from the parent or guardian. 
 
Nasopharyngeal airway sample collection   
 Nasopharyngeal samples were collected by trained site investigators using the same 
standardized protocol utilized in a previous cohort study of children with bronchiolitis (20, 
21). Briefly, 1 mL of normal saline was instilled into one naris, and mucus was removed by 
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means of an 8 French suction catheter. The procedure was performed once on each nostril and 
following sample collection from both nares, 2 mL of normal saline was suctioned through 
the catheter to clear the tubing and ensure that a standard volume of aspirate was obtained. All 
sites used the same collection equipment (Medline Industries, Mundelein, IL) and collected 
the samples within 24 hours of hospitalization. The nasopharyngeal sample was immediately 
placed on ice and then stored at −80 °C until the samples were tested for nasopharyngeal 
airway metabolome and microbiome.  
 
Metabolome testing 
Metabolome testing used 125 μl of nasopharyngeal sample and was performed by 
Metabolon (Durham, NC). All samples were blinded to Metabolon and processed in a random 
order. Metabolome profiling used ultra-high performance liquid chromatography-tandem 
mass spectrometry (UPLC-MS/MS). Details of the sample preparation, metabolome profiling, 
identification of compounds, and quality control may be found in the Online Supplement 
(Supplementary Methods)(22).  
 
Microbiome testing 
 Microbial DNA was extracted from the nasopharyngeal samples using MO BIO 
PowerSoil DNA Isolation Kit (Mo Bio Laboratories; Carlsbad, CA) as described previously 
(8). The 16S rRNA gene sequencing data were generated in earlier work (8). The sequencing 
methods were adapted from those developed for the NIH-Human Microbiome Project (23, 
24). In brief, the 16S rDNA V4 region was amplified by PCR using barcoded Illumina 
adapter-containing primers 515F and 806R (25) and sequenced on the MiSeq platform 
(Illumina; San Diego, CA) using the 2x250 bp paired-end protocol yielding pair-end reads 
that overlap almost completely. Demultiplexing of reads was performed using USEARCH 
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v7.0.1090 (26) and quality filtering was performed as previously described (8). Resulting 
OTU tables were rarified to 1,500 reads per sample.  
 To examine the encoded metabolic potential of nasopharyngeal airway microbiome, 
the current study also applied a metagenomic whole genome shotgun (WGS) sequencing to 
70 nasopharyngeal samples. Individual libraries constructed from each sample were 
sequenced using the 2x100 bp paired-end read protocol on the HiSeq platform (Illumina). The 
process of quality filtering, trimming and demultiplexing was performed using a pipeline 
developed at the Baylor College of Medicine that employs a number of publicly available 
tools such as Casava v1.8.3 (Illumina) for the generation of fastqs, Trim Galore and cutadapt 
for adapter and quality trimming, and PRINSEQ for sample demultiplexing. Additionally, 
Bowtie2 v2.2.1 was used to map reads to custom databases for bacteria, viruses, human, and 
vectors and remove non-bacterial reads from the dataset. For bacterial reads, the highest 
identity match was chosen. If there were multiple top hits, the lowest common ancestor was 
determined, but these reads do not contribute to the analysis. Reads whose genomic 
coordinates overlapped with known KEGG orthologs (K numbers) were tabulated. Coding 
sequences from references genomes that have not been specifically annotated by KEGG were 
aligned to all known KEGG orthologs. Any coding sequence that had >70% identity and 
>70% query coverage to a known KEGG ortholog was assigned to that KEGG ortholog. This 
in effect created links between new genomes and the KEGG database. KEGG modules (M 
numbers) were calculated step-wise and determined to be complete if 65% of the reaction 
steps were present per detected species and for the metagenome as a whole. Pathways were 
constructed for each taxa and metagenome by calculating the minimum set through MinPath 
(27) resulting from the gene orthologs present.  
Details of the microbial DNA extraction, 16S rRNA gene sequencing, and 
metagenomic WGS sequencing may be found in the Online Supplement. Microbiome data 
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have been deposited in the NCBI BioProject (ID PRJNA356075). 
 
Statistical analyses 
 The primary outcome measure was the use of PPV support – defined as the use of 
continuous positive airway pressure and/or intubation – at any time during the index 
hospitalization (20, 28). The analysis followed a workflow to determine the relations among 
the nasopharyngeal airway metabolome profiles, microbiome profiles, and use of PPV 
(Figure E1). Full analytical methodology is described in the Online Supplement. First, to 
examine the differences in nasopharyngeal metabolomic profile between infants with PPV use 
and those without, orthogonal partial least squares-discriminatory analysis (OPLS-DA) was 
performed (29) and validated by permutation testing (2000 permutations). Individual 
metabolites that significantly differ by PPV use were determined using two-tailed Welch’s t-
test in MetaboAnalyst 3.0 (30) and multivariable linear regression in R version 3.3 (31). The 
models adjusted for potential confounders (age, sex, history of prematurity, history of 
antibiotic use prior to the enrollment, use of systemic corticosteroids during the pre-
hospitalization visit, virus, and hospital site). P-values were adjusted for multiple comparisons 
with the false discovery rate (FDR) algorithm (32). To determine the predictivity of 
individual metabolites as a marker for PPV use, receiver operating characteristic (ROC) 
curves were generated by linear support vector machine (SVM) classification with Monte-
Carlo cross validation. In each Monte-Carlo cross validation, two-thirds of the samples were 
used to examine the feature importance based on weighted coefficients, and the important 
features (metabolites) were used to build classification models which were validated using the 
one-third of samples left out. Additionally, to examine pathways that are differentially 
enriched in infants who underwent PPV, pathway enrichment analysis was performed. Next, 
MixOmics (33) was implemented in R to determine the correlation between bacterial taxa and 
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the intensity of metabolites of interest with the use of sparse partial least squares regression in 
canonical mode (34). Furthermore, in order to determine the severity-related differences in 
metabolic potential of the nasopharyngeal microbiome overall and bacterial genera, two-tailed 
Welch’s t-test was used to compare the metagenomic KEGG orthologs (KOs). Lastly, to 
determine biologically feasible correlations between the metagenomic KOs and the measured 
metabolites of likely bacterial origin, the Model-based Integration of Metabolite Observations 
and Species Abundances (MIMOSA) method was used (35).  
 
 
RESULTS 
Study population and analysis workflow 
 As part of 17-center prospective cohort study of 1,016 infants hospitalized for 
bronchiolitis, the current investigation analyzed 144 infants with sufficient amount of 
nasopharyngeal airway sample for metabolome and microbiome testing. The analytic and 
nonanalytic cohorts had no significant differences in most patient characteristics (P>0.05; 
Table E1), except the analytic cohort had a relatively higher proportion of rhinovirus 
infection (28% vs. 20%; P=0.04). Of 144 infants in the analytic cohort, the median age was 3 
months (IQR, 1–6 months) and 25 (17%) underwent PPV during their hospitalization. Infants 
who underwent PPV were younger and more likely to have respiratory syncytial virus (RSV) 
infection compared to those without (both P<0.05; Table 1).  
 
Metabolomics analysis of individual metabolites showed nasopharyngeal metabolomic 
profiles significantly differed by PPV use among infants with bronchiolitis 
 Metabolomic analysis detected a total of 254 metabolites, from 62 sub-pathways, 
contained within 8 super-pathways, in the nasopharyngeal airway of infants with 
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bronchiolitis. The metabolomic profiles (i.e., normalized intensity of individual metabolites, 
irrespective of sub- and super-pathway) clustered distinctly between infants with PPV use and 
those without PPV use in OPLS-DA (Figure E2). The significant difference was validated 
using permutation testing (P<0.001). The individual metabolites that discriminated the infants 
with PPV use from those without included all 20 detected metabolites from the sphingolipid 
metabolism sub-pathway (Figure 1). By contrast, 5-oxoproline, trans-urocanate, 13-HODE-9-
HODE, and 15-HETE were negatively associated with the risk of PPV use.  
 The intensity of these individual metabolites in the infants’ nasopharyngeal airway 
differed by PPV use, with no single metabolite ubiquitously increased among all infants with 
PPV use and decreased among all infants without PPV use, or vice versa. Thus, to determine 
the predictivity of individual metabolites as a marker for higher severity (i.e., use of PPV) at 
the point of hospitalization, we employed multivariate ROC curve analysis (Figure 2A). The 
ROC curve for the top 5, 10, 15, 25, 50, and 100 metabolites showed the area-under-the-curve 
improved with a larger number of metabolites. Model 4 (25 metabolites) and model 6 (100 
metabolites) achieved the highest accuracy with both having a sensitivity of 84% and 
specificity of 86% (Table E2). Given the equivalent accuracy, model 4 was selected as most 
appropriate. Of these 25 metabolites, 12 predicted a higher risk of PPV use and 13 predicted a 
lower risk (Figure 2B). The model performance was validated using permutation testing 
(P<0.001 with 1000 random permutations). 
 
Metabolomics analysis of metabolic pathways showed sphingolipid metabolism is 
significantly enriched among infants who underwent PPV 
 Previous analysis of individual metabolites, irrespective of the sub-pathway, 
demonstrated that the metabolomic profiles differ by PPV use and that 25 metabolites 
accurately predicted PPV use. While these 25 individual metabolites were the most predictive, 
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a total of 103 nasopharyngeal airway metabolites (from 6 super-pathways) significantly 
differed between infants with PPV use and those without (Figure E3). Moving beyond the 
analysis of individual metabolites, we next investigated metabolic pathway enrichment to 
determine which metabolic sub-pathways were significantly associated with risks of PPV use. 
 In accordance with the OPLS-DA (Figure 1), pathway enrichment analysis 
demonstrated that the sphingolipid metabolism sub-pathway (super-pathway: lipid) was the 
most significantly associated with risks of PPV use (P<0.001; Figure E4). Indeed, all 20 
detected metabolites from this pathway were significantly more abundant in infants with PPV 
use compared to those without. Even after adjusting for potential confounders, 19 out of the 
20 metabolites remained significant (all P<0.05; Figure 3 and Table E3). To address the 
possibility of reverse causation (i.e., the use of PPV enhanced sphingolipid metabolism), we 
repeated the analysis with the use of another severity outcome – hospital length-of-stay ≥3 
days (8). In this sensitivity analysis, the association between up-regulated sphingolipid 
metabolism and higher disease severity persisted, with 17 out of 20 sphingolipid metabolites 
remaining significant with adjustment for potential confounders (all P<0.05; Table E3).  
 Although many metabolites do not currently have corresponding KEGG compound 
identifiers, 5 of the 20 significant sphingolipid metabolites had corresponding KEGG 
compound numbers and mapped throughout the KEGG sphingolipid metabolism pathway 
(Figure E5). Other sub-pathways with significant enrichment included the 
phosphatidylethanolamine (P<0.001), plasmalogen (P<0.001), and phosphatridylcholine 
(P<0.001) from the lipid super-pathway, and the glycine, serine, and threonine metabolism 
(P=0.02) sub-pathway from the amino acid super-pathway (Figures E3 and E4).  
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Microbiome and metabolomic analysis showed Streptococcus relative abundance 
positively correlates with intensities of metabolites that predict risks of PPV use and 
with enrichment of sphingolipid metabolism pathway 
 Taxonomic data generated by 16S rRNA gene sequencing and metagenomic WGS 
were comparable, showing Haemophilus, Moraxella, and Streptococcus genera dominated 
nasopharyngeal airway of infants with bronchiolitis (Figure E6A and B). The relative 
abundance of these genera was also comparable between sequencing approaches (Figure E7). 
The metagenomic sequencing (n=70; Table E4) permitted species-level identification and 
further demonstrated that Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus 
pneumoniae specifically dominated the nasopharyngeal airway (Figure E6C).  
 To determine the potential microbe-host interaction in the airway of infants with 
bronchiolitis, we examined the correlations between the relative abundance of the 3 dominant 
bacterial genera (Streptococcus, Moraxella, and Haemophilus) with the relative intensity of 
selected metabolites that were identified in the previous analyses (metabolites in model 4 and 
sphingolipid metabolism). The relative abundance of Streptococcus was positively correlated 
with the majority (11/12) of metabolites predicting high risks of PPV use from model 4 
(Figure 4A). By contrast, the relative abundance of Moraxella and Haemophilus was 
generally negatively correlated with relative intensity of the same metabolites. These 
correlations were comparable in the sphingolipid metabolism pathway analysis, in which the 
relative abundance of Streptococcus was also positively correlated with the relative intensity 
of all metabolites from the sphingolipid metabolism pathway (Figure 4B). 
  
Bacterial gene orthologs are distinct between infants with PPV use and those without  
 Lastly, the metagenome was analyzed to investigate potential differences in the 
metabolic potential of the nasopharyngeal microbiome according to use of PPV. 
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Metagenomic sequencing identified a total of 285 KOs that were differentially enriched 
between infants with PPV and those without (173 KOs vs 112 KOs, respectively; all P<0.05; 
Table E5). KOs significantly enriched in infants with PPV use were primarily from 
Streptococcus sp. (33 KOs), Rothia sp. (33 KOs) and Klebsiella sp. (27 KOs). Additionally, 6 
KOs from Haemophilus sp. were also significantly enriched among infants with PPV use. 
Conversely, all 112 KOs significantly enriched in infants without PPV use were from 
Moraxella catarrhalis. 
 At the individual metabolite level, MIMOSA analysis demonstrated the metagenomic 
KOs were significantly correlated with 15 measured metabolites, primarily amino acids 
(Table E6). Notably, the abundance of seryl-tRNA synthetase (KO1875) from Streptococcus 
pneumoniae was correlated with the intensity of serine (substrate of sphingosine). However, 
there was no significant correlation between the abundance of metagenomic KOs and the 
intensity of the metabolites that were significantly altered by PPV use (e.g. metabolites from 
sphingolipid metabolism), suggesting that the PPV-related measured metabolites (and 
pathways) are likely host derived.  
 
 
DISCUSSION 
 In a multicenter prospective cohort of infants hospitalized for bronchiolitis, we used 
three complementary methodologies to characterize the nasopharyngeal airway metabolome, 
microbiome composition, and metagenome in samples collected at hospitalization. This is the 
first multi-omic analysis integrating these distinct methodologies to determine the association 
of airway metabolome and microbiome with severity of illness in infants with bronchiolitis. 
We found that the nasopharyngeal airway metabolome profiles significantly differed by PPV 
use. A panel of 25 selected metabolites provided high sensitivity (84%) and specificity (86%) 
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in predicting the use of PPV. Strikingly, all detected metabolites from the sphingolipid 
metabolism sub-pathway were discriminatory for PPV use by OPLS-DA, and sphingolipid 
metabolism was the most significantly enriched sub-pathway among infants with PPV use, 
with 19 out of 20 metabolites within this pathway significant even after adjusting for potential 
confounders. These findings were further validated using length of hospitalization as another 
marker for severity. The data also demonstrated that the association between higher 
abundances of Streptococcus and enriched sphingolipid metabolites, suggesting that the 
alterations of these metabolites are the result of a combination of microbial and metabolic 
activity. 
 Sphingolipids are not only integral components of the eukaryotic cell membrane, but 
also have molecular signaling functions with important roles in inflammation, immune 
response to infections, stress response, cell proliferation, and apoptosis (36–38). While the 
current study is the first to apply metabolomics to infant nasopharyngeal samples, metabolites 
associated with sphingolipid metabolism have been reported to increase in a range of existing 
studies investigating pulmonary disorders in childhood and adulthood (36, 37). For example, 
sphingolipids were primarily significantly increased in sputum from adults with CF compared 
to healthy controls (17). Additionally, sphingolipids directly promoted airway inflammation 
and were increased in the bronchoalveolar lavage fluid in patients with asthma compared with 
healthy controls (39, 40). Furthermore, multi-omic analysis of plasma in children with asthma 
also demonstrated altered metabolic functioning, primarily due to increased sphingolipid 
metabolism (15).  
In a different line of inquiry, novel therapeutic agents have also targeted 
sphingolipids. It has been shown in an asthma murine model that inhalation of a sphingosine 
kinase inhibitor reduced inflammation and airway hyperresponsiveness, and improved 
immune responses (41). In a more recent murine study, inhibition of sphingosine kinase 
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suppressed pro-inflammatory NF-κB and reduced airway inflammation (42). While these 
aforementioned studies do not directly investigate bronchiolitis, they link sphingolipid 
metabolism to inflammatory-mediated pathogenesis of airway diseases, and thereby support a 
potential role of sphingolipids in the pathobiology of bronchiolitis. 
  Amplicon sequencing of upper airway samples from children with respiratory 
infection has demonstrated an association between microbial dominance in the airway and 
illness severity. Moraxella has been associated with decreased severity of illness in infants 
hospitalized with bronchiolitis (8), while Streptococcus or Haemophilus have been associated 
with increased severity (7, 9, 43) and reduced microbiome stability (44). Consistent with 
these studies, our multi-omic analysis demonstrated that the abundance of Moraxella was 
generally negatively correlated with the intensity of metabolites associated with PPV use, and 
M. catarrhalis contributed to all metagenomes significantly enriched among infants without 
PPV use. By contrast, the relative abundance of Streptococcus was positively correlated with 
the intensity of PPV-associated metabolites. These bacteria-metabolite correlations persisted 
for both the individual metabolites (model 4) and the sphingolipid metabolism sub-pathway.  
Our multi-omic analysis brings together microbiome and metabolome data and 
yielded findings that are concordant with recent studies exploring respiratory infections. In 
adults with CF, Streptococcus abundance in sputum was correlated with the relative intensity 
of metabolites involved in sphingolipid metabolism, including ceramide (18:2/16:0) and 
sphingomyelin (16:1/16:0) (16). A separate study investigating adults with S. pneumonia and 
H. influenza pneumonia and controls showed that plasma sphingolipids were primarily 
responsible for discrimination between patients with pneumonia and controls (45). 
Interestingly, our data also demonstrated that the metagenome-derived function of 
nasopharyngeal microbiome is not directly correlated with the intensity of metabolites that are 
associated with PPV use. This suggests that the significantly discriminant metabolites and 
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pathways (e.g., sphingolipid pathway) are unlikely to be microbiome-derived, but rather 
produced by the host. While further work is necessary to confirm this, most bacteria do not 
produce sphingolipids, which is especially true for aerobic bacteria, such as those found in the 
airways (46). Nevertheless, it is notable that the metagenomic data demonstrated S. 
pneumoniae to generate serine, a substrate of sphingosine – the fundamental building block of 
all sphingolipids. Thus, while the sphingolipid metabolites are host derived, exogenous serine 
generated by S. pneumoniae may contribute to the significantly increased sphingolipid 
metabolism in the airway of infants with bronchiolitis. 
The nature of the observed airway microbiome composition-metabolome-severity 
relations warrants clarification. It is possible that the airway microbiome contributed to higher 
bronchiolitis severity by modulating host cellular function and metabolism (e.g., sphingolipid 
metabolism). Alternatively, following a change in host metabolism certain species (e.g., S. 
pneumoniae) were able to proliferate (47–49). Additionally, reverse causation is possible – 
i.e., more severe bronchiolitis not only led to an overgrowth of specific bacteria in the airway 
niche, but also altered host cellular metabolism. We also recognize that these mechanisms are 
not mutually exclusive. Our data should facilitate further research to elucidate the underlying 
mechanisms linking the microbes, host immune response, and altered metabolism in the 
airway to bronchiolitis pathogenesis.  
 
Potential limitations 
 The current study has several potential limitations. First, nasopharyngeal samples 
were used due to technical and ethical restrictions in sampling lower airways from young 
infants. However, studies have shown that upper airway sampling provides reliable 
representation of the lung microbiome (50, 51) and gene expression profiles (as a proxy for 
cellular function) in children (52). Second, this study was not able to directly prove causality, 
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but depletion of sphingolipid metabolism prevents disease onset in murine models of 
inflammatory mediated respiratory diseases, supporting our data for the role of this sub-
pathway in bronchiolitis severity (41, 42). Third, while the current study demonstrated the 
findings to be robust by performing analytical validation, external validation would be 
necessary to confirm the observations. Fourth, the inferences using 16S rRNA gene 
sequencing data were potentially limited because of their compositionality and may have led 
to false positives in correlation and statistical analyses (53, 54). Fifth, while the intensity of 
sphingolipids was significantly associated with risks of PPV use independently from age, 
history of antibiotic use, and other adjusted covariates, it is possible that some of observations 
might have been confounded by age. Additionally, our binary adjustment of antibiotic use 
assumes any exposure to antibiotics to be comparable, regardless of type and duration. 
Potential effects of antibiotic type and time course were not accounted for in our models. 
Sixth, we did not have information from a “control” group, such as infants with non- 
infectious disease. Yet, the objective of the current study was not to examine the role of 
metabolome and microbiome on the development of bronchiolitis but to determine their 
relationships with disease severity. Last, longitudinal studies would advance understanding of 
temporal changes in bacterial taxa and metabolites prior to bronchiolitis onset. Nonetheless, 
investigations into disease severity among infants hospitalized with bronchiolitis remain an 
important research focus given the high incidence (the leading cause of infant 
hospitalization). 
 
Conclusions 
 In summary, this multi-omics analysis of nasopharyngeal samples collected 
prospectively from a multicenter cohort of infants hospitalized for bronchiolitis demonstrated 
that the metabolomic profiles differ by use of PPV (clinically important marker of disease 
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severity). We also found that, among 254 metabolites identified, a panel of 25 metabolites 
showed high sensitivity and specificity in discerning the use of PPV. Although external 
validation of the present findings is required, the ability to predict disease severity, 
specifically the need for respiratory support, has important implications for the clinical 
management of infants with bronchiolitis. Furthermore, our data demonstrated that the 
sphingolipid metabolism pathway was the most significantly enriched sub-pathway among 
infants who underwent PPV and that its enrichment was positively correlated with the 
abundance of Streptococcus. Emerging data suggest several important roles that sphingolipid 
metabolism may play in airway disease pathogenesis. Our findings support further 
experimental investigations to define the function of sphingolipids in acute respiratory 
infections, which may provide a novel therapeutic strategy to treat infants with severe 
bronchiolitis. 
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TABLE 
Table 1. Characteristics of 144 infants hospitalized for bronchiolitis by use of positive 
pressure ventilation  
 
Data are no. (%) of infants unless otherwise indicated.  
Abbreviation: IQR, interquartile range  
* Includes parainfluenza virus types 1, 2, and 3, influenza virus types A and B, 2009 novel 
H1N1, human metapneumovirus, coronaviruses NL-65, HKU1, OC43 and 229E, adenovirus, 
human bocavirus type 1, and enterovirus 
 
  
 
 
Characteristics 
Use of positive 
pressure 
ventilation  
(n = 25) 
No positive 
pressure 
ventilation use 
(n = 119) 
 
P Value 
Age (mo), median (IQR) 1.4 (1.0-3.0) 3.0 (1.4-5.7) 0.02 
Male sex 14 (56%) 74 (62%) 0.56 
Race/ethnicity   0.21 
   Non-Hispanic white 15 (60%) 55 (46%)  
   Non-Hispanic black 2 (8%) 22 (18%)  
   Hispanic 5 (20%) 36 (30%)  
   Other 3 (12%) 6 (5%)  
Maternal smoking during pregnancy 2 (8%) 10 (8%) 0.98 
Prematurity (32-37 weeks) 4 (16%) 27 (23%) 0.46 
C-section delivery  9 (36%) 44 (37%) 0.78 
Postnatal smoke exposure at home 0 (0%) 16 (13%) 0.052 
Number of siblings, median (IQR) 1 (0-5) 1 (0-5) 0.45 
History of antibiotic use prior to enrollment 6 (24%) 41 (34%) 0.3 
History of corticosteroid use prior to enrollment 3 (12%) 19 (16%) 0.61 
Virology    
   RSV infection 23 (92%) 85 (71%) 0.03 
   Rhinovirus infection 3 (12%) 37 (31%) 0.053 
   Neither RSV nor rhinovirus* 2 (8%) 3 (3%) 0.21 
Positive pressure ventilation use    
   Non-invasive positive pressure ventilation 14 (56%) 0 (0%) − 
   Invasive positive pressure ventilation 18 (72%) 0 (0%) − 
   Both 7 (28%) 0 (0%) − 
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FIGURE LEGENDS 
Figure 1. Orthogonal partial least squares-discriminatory analysis (OPLS-DA) loadings 
plot of nasopharyngeal airway metabolomics among infants with bronchiolitis (n=144). 
This loadings plot combines the covariance (x-axis) and correlation (y-axis) loading profiles 
resulting from OPLS-DA model. This corresponds to combining the contribution (covariance) 
with the effect and reliability (correlation) for the model variables (metabolites) with regard to 
the risk of PPV use. In this figure, we selected and labeled metabolites with higher covariance 
and correlation that are significantly associated with a higher risk of PPV use (red) or lower 
risk (blue) in the subsequent analysis. Score scatter plot may be found in supplement (Figure 
E2). 
Abbreviation: PPV, positive pressure ventilation 
 
 
Figure 2. Support vector machine (SVM) biomarker analysis predicting the risk of 
positive pressure ventilation use among infants with bronchiolitis (n=144). (A) Linear 
SVM ROC curves showing increased area under the curve with increased numbers of 
metabolites. After model 4 (sky blue – 25 metabolites), the prediction was not improved 
materially, as per Table E2. Model 4 had a sensitivity of 84% and specificity of 86%. (B) 
Average importance of metabolites from Model 4 (25 metabolites) in predicting the use (or 
non-use) of PPV based on SVM feature ranking.   
Abbreviation: PPV, positive pressure ventilation  
 
Figure 3. Bar plots of the 20 metabolites from the sphingolipid metabolism sub-pathway 
by use of PPV. Bars represent the average scaled intensity. After adjusting for potential 
confounders, the intensity of 19 out of 20 metabolites within the sphingolipid metabolism 
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pathway were significantly different between infants who underwent PPV and those who did 
not.  
* Denotes significance (P<0.05). 
Abbreviation: PPV, positive pressure ventilation 
 
Figure 4. Canonical correlation between nasopharyngeal airway microbiota and 
metabolites associated with positive pressure ventilation use (n=144). Relative abundance 
for the three dominant genera is based on 16S rRNA gene sequencing. Red text indicates 
metabolites that are associated with a higher risk of PPV use; blue text indicates metabolites 
that are associated with a lower risk of PPV use. (A) Canonical correlation between the 
relative abundance of dominant bacterial genera and the 25 metabolites from model 4. 
Streptococcus abundance was positively correlated with the intensity of most metabolites 
from model 4 that are associated with a higher risk of PPV use, such as mannitol-sorbitol, 
methyl-4-hydroxybenzoate, and 3-(4-hydroxyphenyl)lactate. (B) Canonical correlation 
between the relative abundance of three dominant bacterial genera and the 20 metabolites 
within the sphingolipid metabolism pathway. Streptococcus abundance was positively 
correlated with the intensity of all 20 metabolites within the pathway.  
